Form 4 for MIRM Mirum Pharmaceuticals, Inc.
Accepted 2026-07-08 17:12:48 ET · period of report 2026-07-06 · accession 0001614740-26-000011 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-07-08 17:12 | 2026-07-06 | MIRM | Peetz Christopher | CEO, Dir | M - OptEx | $2.94 | +20.0K | 214.3K | +10% | +$58.7K |
| DMT | 2026-07-08 17:12 | 2026-07-06 | MIRM | Peetz Christopher | CEO, Dir | S - Sale+OE | $122.27 | -20.0K | 194.3K | -9% | -$2.45M |
| DT | 2026-07-08 17:12 | 2026-07-06 | MIRM | Peetz Christopher | CEO, Dir | M - OptEx | $0.00 | -20.0K | 108.5K | -16% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-06 | M | A | 20,000 | $2.94 | 214,309 | D | — | — | |
| 2 | Common | Common Stock | 2026-07-06 | S | D | 12,134 | $121.65 | 202,175 | D | — | — | (F1) Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 2, 2026. (F2) The weighted average sale price for the transaction reported was $121.65, and the range of prices were between $121.11 and $122.105. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 3 | Common | Common Stock | 2026-07-06 | S | D | 4,181 | $122.34 | 197,994 | D | — | — | (F1) Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 2, 2026. (F3) The weighted average sale price for the transaction reported was $122.34, and the range of prices were between $122.13 and $123.1125. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 4 | Common | Common Stock | 2026-07-06 | S | D | 1,975 | $123.74 | 196,019 | D | — | — | (F1) Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 2, 2026. (F4) The weighted average sale price for the transaction reported was $123.74, and the range of prices were between $123.24 and $124.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 5 | Common | Common Stock | 2026-07-06 | S | D | 1,710 | $124.79 | 194,309 | D | — | — | (F1) Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 2, 2026. (F5) The weighted average sale price for the transaction reported was $124.79, and the range of prices were between $124.27 and $124.94. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 6 | Derivative | Employee Stock Option (right to buy) | 2026-07-06 | M | D | 20,000 | $0.00 | 108,487 | D | $2.94 · — to 2029-03-11 | 20,000 Common Stock | (F6) The stock option is fully vested. |